Danaher Co. (NYSE:DHR) Holdings Increased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in shares of Danaher Co. (NYSE:DHR) by 2.6% during the second quarter, Holdings Channel reports. The institutional investor owned 3,398,649 shares of the conglomerate’s stock after acquiring an additional 85,081 shares during the period. Dimensional Fund Advisors LP’s holdings in Danaher were worth $849,195,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cape Investment Advisory Inc. bought a new stake in shares of Danaher during the 4th quarter worth about $25,000. Tsfg LLC raised its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the 2nd quarter worth about $25,000. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the 1st quarter worth approximately $30,000. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares of the company’s stock, valued at $11,501,145.50. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DHR. Evercore ISI lowered their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Finally, Wells Fargo & Company started coverage on shares of Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Stock Performance

Shares of DHR opened at $274.25 on Monday. The company’s 50 day moving average price is $264.55 and its 200 day moving average price is $256.51. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a market capitalization of $198.07 billion, a PE ratio of 46.48, a PEG ratio of 4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.05 earnings per share. Research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.